BUSINESS
Astellas, Cytokinetics Agree to Develop, Commercialize Skeletal Muscle Activators
Astellas Pharma announced on June 26 that it has formed an agreement with US-based Cytokinetics to collaborate in the research, development, and commercialization of skeletal muscle activators. Astellas and the American biotech firm will codevelop CK-2127107, a fast skeletal troponin…
To read the full story
Related Article
- Astellas, Cytokinetics Expand Collaboration into ALS
July 29, 2016
BUSINESS
- AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
- Enhertu Combo Wins US FDA Nod in 1st-Line HER2 Breast Cancer
December 17, 2025
- Pfizer Releases Nurtec Migraine Drug in Japan
December 17, 2025
- Towa Lifts Atomoxetine Shipment Curbs Across All Strengths
December 17, 2025
- Daiichi Sankyo Targets Cancer Cure with IO-ADC Combo Strategy
December 17, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





